Slide 1: Results Presentation filing letter to BSE and NSE
May 27, 2026 BSE Ltd., National Stock Exchange of India Ltd., P J Towers, Exchange Plaza, Dalal Street, Bandra-Kurla Complex, Bandra, Mumbai - 400 001. Mumbai - 400 051. Scrip Code: 524735 Symbol: HIKAL Dear Sir/Madam, Subject: Results Presentation of the Company for the quarter and financial year e
Slide 2: Investor Presentation Q4 & FY26
Investor Presentation Q4 & FY26 May 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and
Slide 4: Leading with Vision
Leading with Vision Q4, FY26 marks an improvement in Hikal’s operating performance. The company is moving decisively from a phase of remediation and normalization to one of sustainable growth. Mr. Jai Hiremath, Executive Chairman For Q4 FY26, we delivered Revenue of Rs. 519 Cr. and an EBITDA margin
Slide 5: Q4 & FY26: Performance at a Glance
Q4 & FY26: Performance at a Glance
Slide 6: Q4FY26: Consolidated Performance Summary
Q4FY26: Consolidated Performance Summary CONSOLIDATED: FINANCIAL SUMMARY COMMENTARY Rs. In Crs Q3FY26 Q4FY25 Q4FY26 The Total Dividend for the year is 30% including a final dividend of 20% Revenue 494 552 519 Quarterly EBITDA of Rs. 105 crores with Margins of 20.3% EBITDA 83 123 105 PAT for the quar
Slide 7: Q4FY26: Pharmaceuticals Performance Summary
Q4FY26: Pharmaceuticals Performance Summary PHARMACEUTICALS: FINANCIAL SUMMARY COMMENTARY Rs. In Crs Q3FY26 Q4FY25 Q4FY26 Pharmaceutical business witnessed sequential improvement in EBIT margins due to better product mix Revenue 337 351 292 H2 FY26 Pharma Revenue grew by 60% to Rs. 629 crores over H
Slide 8: Q4FY26: Crop Protection Performance Summary
Q4FY26: Crop Protection Performance Summary CROP PROTECTION: FINANCIAL SUMMARY COMMENTARY Rs. In Crs Q3FY26 Q4FY25 Q4FY26 Crop Revenues for the quarter grew 45% QoQ and 13% YoY to Rs. 228 crores Revenue 157 201 228 H2 FY26 Crop Revenue grew 25% to Rs. 385 crores from H1 FY26 at EBIT 5 36 39 Rs. 307
Slide 9: Q4FY26: Consolidated P&L
Q4FY26: Consolidated P&L Particulars (Rs. In Q4FY26 Q4FY26 Q4FY25 YoY Q3FY26 Q3FY26 QoQ crores) incl. w/o (with w/o incl. (with exceptional exceptional exceptional) exceptional exceptional exceptional) item item item item Revenue 519 519 552 -6% 494 494 5% Expenditure 414 414 429 411 411 EBITDA 105
Slide 10: FY26: Performance at a Glance
FY26: Performance at a Glance
Slide 11: FY26: Performance Summary
FY26: Performance Summary FINANCIAL SUMMARY REVENUE SPLIT% Rs. In Crs FY25 FY26 In % FY25 FY26 Consolidated Revenue 1,860 1,713 Pharmaceuticals 62% 60% EBITDA 328 220 Crop-Protection 38% 40% EBITDA% 17.7% 12.9% PAT 91 49 EPS 7.36 -3.96 Pharmaceuticals Rs. In Crs FY25 FY26 In % FY25 FY26 Revenue 1,16
Slide 12: FY26: Consolidated P&L
FY26: Consolidated P&L Particulars (Rs. In crores) FY26 FY26 FY25 YoY w/o exceptional incl. exceptional (with exceptional) item item Revenue 1,713 1,713 1,860 -8% Expenditure 1,492 1,492 1,532 EBITDA 220 220 328 -33% EBITDA Margin 12.9% 12.9% 17.7% -479 bps Other Income 12 12 5 Depreciation 164 164
Slide 13: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs. In Crore) Mar-26 Mar-25 Equities & Liabilities (Rs. In Crore) Mar-26 Mar-25 Total Non Current Assets 1,481 1,534 Shareholders Fund 1,199 1,262 Property, Plant and Equipment 1,264 1,293 Share Capital 25 25 Capital work in Progress 95 121 Other Equity 1,174 1,238
Slide 14: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. In Crore) Year ended 31-Mar-26 Year ended 31-Mar-25 Profit before tax (78) 124 Adjustments 278 215 Operating Profit Before Working Capital Changes 200 339 Change in operating assets and liabilities 117 (29) Cash generated from operations 316 310 Inco
Slide 15: Historical Performance Highlights
Historical Performance Highlights
Slide 16: Historical: Consolidated P&L Highlights
Historical: Consolidated P&L Highlights Rs. In crores REVENUE EBITDA PAT (excl. Exceptional Item*) 2,023 161 341 328 1,943 257 267 1,860 220 91 1,785 78 70 1,713 5 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 *Exceptional item is due to effect of new labour code (Rs. 47
Slide 17: Historical: Segmental Highlights
Historical: Segmental Highlights Rs. In crores REVENUE EBIT REVENUE SPLIT % 1,168 151 137 Own product CDMO 1,130 1,115 1,100 93 65 44% 41% 35% 42% PHARMA 1,021 52% 33 56% 59% 65% 58% 48% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 REVENUE EBIT REVENUE SPLIT % 908 Own p
Slide 18: Historical: Ratios
Historical: Ratios ROE% (excl. exceptional Item) ROCE% 21.6% 15.0% 9.9% 12.6% 8.5% 8.2% 7.1% 6.1% 3.5% 3.0% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 NET DEBT / EQUITY (X) NET DEBT / EBITDA (X) 0.7 2.9 0.6 0.6 0.6 0.6 2.6 2.3 1.8 1.8 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 17
Slide 19: Corporate Snapshot
Corporate Snapshot
Slide 20: Our Vision & Mission
Our Vision & Mission VISION To be the leading global fine chemical company to the Pharmaceutical, Crop Protection, and Specialty Chemical Industries 01 02 MISSION To create value through superior, chemical products and operate as a responsible company. Building trust and respect of our customers, sh
Slide 21: Key Milestones
Key Milestones Years 1988 1991 1995 1997 2000 2001 2009 2014 2021 2024 Founded Listed on Acquired the New R&T Signed 10- by Jai Bombay Stock manufacturing Centre year multi Hiremath Exchange & site from established & product Key Event as a National Stock Novartis in Tokyo office to contract with che
Slide 22: Domestic & Global Presence
Domestic & Global Presence We Service Clients Globally Through our Global Footprint Panoli Europe Taloja Japan USA Pune Navi Mumbai India Bengaluru Mahad Corporate HQ R&T center, Integrated Mini Plant Manufacturing Site We serve markets across Americas, Europe, ME & We have offices across USA, Europ
Slide 23: Manufacturing Capabilities
Manufacturing Capabilities Pharmaceuticals Crop Protection Jigani Unit 1, Karnataka Mahad, Maharashtra • US FDA Approved API and Advanced Intermediates • First Manufacturing Facility of Hikal Manufacturing Site • Specialty Chemicals, Fungicides, Herbicides, and • cGMP Multipurpose API Facilities. In
Slide 24: Our state-of-the-art R&T facility
Our state-of-the-art R&T facility 15 4 Synthetic Instrumentation Laboratories Labs 1 1 Process Effluent Safety Treatability Lab Lab 1 1 Innovation Simulation 1 1 Lab Lab Kilo Lab Solid State (Scale up & Pilot) Chemistry Lab 1 6 Process High Development 1 1 Pressure Lab Lab Validation HPAPI Lab Lab >
Slide 25: Innovation & New Technology – Taloja Kilo Lab
Innovation & New Technology – Taloja Kilo Lab Business Opportunity Specialty Chemical Leadership: Crop protection and specialty chemicals are innovation-driven, high-growth segments globally, with rising demand for complex and differentiated chemistries. CDMO Partnership: Entry into high-value, comp
Slide 26: Key Operational Metrics
Key Operational Metrics Pharmaceuticals Crop Protection 5 Manufacturing facilities 31 74 Commercialized Active DMFs Products 31 4,350MT $60Mn Commercialized Active Ingredients Capex invested in new Assets APIs Sold in FY25 440MT Advanced Intermediates 1 Kilo lab Sold in FY25 (Scale up & Pilot) 3000+
Slide 27: Regulatory Approvals
Regulatory Approvals Key Regulatory Approvals Integrated Management Systems across all sites 26
Slide 28: CSR Update
CSR Update Focus on being a Responsible Company by funding initiatives for environment, education, healthcare, & national heritage Anahat Kaushalya & Suraksha Medha Rachana Environment & Ecology protection Healthcare and Safety Education & skill development Protection of Heritage, Art & Culture Supp
Slide 29: Human Resources Update
Human Resources Update Initiatives taken to enhance employee engagement, learning & development Connect Capability Culture Safety Week Celebration at all sites POSH & Code of Conduct, Ethics & Republic Day and Holi celebrated at all Corporate Governance Training E-learning locations Chairman and Lea
Slide 30: Recognitions & Achievements
Recognitions & Achievements
Slide 31: Awards & Accolades
Awards & Accolades The Great Managers Award 2025 ET NOW Best Organizations to Work TISS Leapvault CLO Awards 2025 Ranked among the Top 50 Companies The ET Now Best Organizations to Work Gold Award for Best Skill Development with Great Managers by People Business 2025 is a prestigious recognition Ini
Slide 32: Thank You
Thank You Company: Investor Relations Advisors : Hikal Limited Strategic Growth Advisors Pvt. Ltd CIN: L24200MH1988PTC048028 CIN: U74140MH2010PTC204285 Mr. Kuldeep Jain Mr. Jigar Kavaiya / Ms. Ami Parekh Kuldeep_jain@hikal.com +91-99206 02034 / +91 80824 66052 jigar.kavaiya@sgapl.net/ ami.parekh@sga